Drug Trial Radar · NCT01030783
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Dec 2009
Primary completion
Jul 2012
Study completion Jun 2013
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
Conditions
- Advanced Renal Cell Carcinoma
Interventions
tivozanib (AV-951)Drug
Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
SorafenibDrug
Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or SorafenibTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.
Locations
86 sites in 16 countries. Site status is shown where the registry gives one.
Site 185
Los Angeles, California
Site 180
Gainesville, Florida
Site 184
Orlando, Florida
Site 182
Minneapolis, Minnesota
Site 186
New York, New York
Site 187
Dallas, Texas
Site 102
Sante Fe, Argentina
Site 403
Plovdiv, Bulgaria
Site 404
Sofia, Bulgaria
Site 400
Sofia, Bulgaria
Site 401
Varna, Bulgaria
Site 402
Veliko Tarnovo, Bulgaria
Site 110
Montreal, Quebec, Canada
Site 122
Santiago, Chile
Site 123
Temuco, Chile
Site 121
La Reina, Santiago de Chile, Chile
Site 411
Prague, Czechia
Site 130
Marseille, France
Site 133
Saint-Herblain, France
Site 423
Budapest, Hungary
Site 421
Kaposvár, Hungary
Site 422
Pécs, Hungary
Site 424
Szombathely, Hungary
Site 154
Delhi, India
Site 157
Hyderabad, Andhra Pradesh, India
Site 190
Patna, Bihar, India
Site 156
Ahmedabad, Gujarat, India
Site 151
Nashik, Maharashtra, India
Site 153
Pune, Maharashtra, India
Site 159
Pune, Maharashtra, India
Site 191
Jaipur, Rajasthan, India
Site 155
Jaipur, Rajasthan, India
Site 152
Vellore, Tamil Nadu, India
Site 158
Lucknow, Uttar Pradesh, India
Site 150
Kolkata, West Bengal, India
Site 160
Arezzo, Italy
Site 161
Pavia, Italy
Site 162
Roma, Italy
Site 432
Bialystok, Poland
Site 434
Bydgoszcz, Poland
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.